represented in the formal EuSANH organisation, and more are expected to join in the near future.
Collaboration within EuSANH received a strong impulse when it received European
Funding in the 7th framework programme (2009-2011) for a three-year project entitled
Improving Science Advice for Health in Europe (EuSANH-ISA, agreement number 229716). Six members conducted the studies, while the others had an advisory role.
During this programme, a common methodological framework for science advice, a first
European science advice and a sustainable EuSANH structure have been developed.
This report describes the results of the first EuSANH science advice.
For more information and detailed reports on the EuSANH-ISA studies, please visit www.eusanh.eu or contact the EuSANH coordinating secretariat Ms Dorine Coenen, d.coenen@gr.nl or eusanh@eusanh.eu.
Objective
The objective is to produce a pilot case study for a European science advisory report, thereby illustrating the common methodology developed by the EuSANH-ISA project and the functioning of the EuSANH network.
Scientific advice for health is defined as a solicited or unsolicited analysis of a defined public health, health care, or health policy problem, based on updated scientific knowledge and taking into consideration relevant expert judgment, practical experience, The science advisory report "Determinants of a successful implementation of population based cancer screening programmes" aims to analyse the processes and procedures needed to successfully implement population-based screening programmes for cervical, breast, and colorectal cancer.
Background
Recent reports have addressed the uptake and practice of cancer screening programmes, Journal of Cancer demonstrated and discussed major differences in performance and coverage of cervical cancer screening in the European Union.
The European Union has published detailed guidelines for cancer screening programmes.
In December 2003, the Council of the European Union presented a recommendation on cancer screening. This recommendation stated that scientific evidence is available concerning the efficacy of screening for breast, colorectal, and cervical cancer. It also stated that ethical, legal, social, medical, organisational, and economic aspects must be considered before decisions can be made to implement screening programmes. However, the existing guidelines are not always implemented. Hence, policy makers need additional evidence and recommendations addressing critical factors for successful cancer screening. EuSANH-ISA, 229716
Framing the questions
Questions: What are the important organisational aspects when implementing cancer screening programmes? How can barriers to participation in organised screening programmes be reduced? What advice can be given to decision makers in a European country that want to initiate or improve a cancer screening programme?
It is important that the scientific advice given is relevant for any European country, regardless of the present organisation of their health care system or if an organised cancer screening programme already exists or is being planned.
This report is intended for the Minister of health in any European country. Hence, the report focuses on general aspects and success factors that can be extrapolated from one cancer screening programme and applied to another. The aim is to help an interested region or country initiate or improve the implementation of a cancer screening programme.
Methodology

Using the EuSANH methodological framework
The EuSANH-ISA project has developed a handbook "A framework for science advice on health: principles and guidelines", which includes guidelines for framing the issue and drafting the advisory report. The handbook will be reported separately. Annex 3 presents the seven consecutive steps and the ten principles in producing a science advice. An evaluation of the advisory process is presented in Annex 4.
A draft of the handbook was presented at the start of the workshop and followed when producing the pilot on scientific advice for implementing cancer screening.
The time frame for producing this pilot case study appears below. In summary, the time from formulating the question to submitting the report was 12 months. 
Using available evidence
Evidence already available in the form of national science advisory reports, systematic reviews, and EU guidelines served as a basis for producing the scientific advice. The Swedish Council on Health Technology Assessment, SBU, produced a background material for the workshop, including an overview of systematic reviews on the topic of participation rates and informed decision making, and also a literature review of organisational and health-economic aspects of cancer screening (www.eusanh.eu, Annex 5). The background document also included an introduction, focusing on the policy perspective and implementation, written by Leo van Rossum and Rosella Hermens.
Expert judgement
An Expert Committee was established, including professionals from different European The workshop began with scientific presentations by participants; illustrating key issues regarding cancer screening implementation in Europe (www.eusanh.eu, Annex 6). These presentations were followed by a general introduction to the purpose of the workshop, including an explanation of the principles and guidelines to enhance the quality and efficiency of the scientific advice. The Committee was officially installed after the experts had presented potential conflicts of interest.
Discussion by Expert Committee
The Committee was divided into two working groups: one tasked with the initial assignment to complete the background document on participation rates and informed decision making, and the other tasked with discussing organisational issues.
On the first day, one of the groups concluded that organised population-based screening is a prerequisite for providing recommendations on determinants. Hence, they suggested drafting a document on the general topic "Determinants of successful implementation of It was also agreed that a statement should be drafted, which should go beyond the evidence base and include the expert judgement of the Committee ("Advice to the Minister"). The experts could choose which document they preferred to work on and were again divided into two groups. By the end of the meeting, the two documents had been drafted and experts had been assigned to complete and circulate them for comments. 
Evaluation
Advice
Any policy decision in Europe to implement a cancer screening programme should take into account EU recommendations and guidelines based on the available evidence and the experience in Europe in implementing population-based cancer screening programmes. Key references in this regard are the Recommendation on Cancer
Screening of 2 December 2003 of the Council of the European Union (1), the European
Guidelines on quality assurance in breast, cervical and colorectal cancer screening (2) (3) (4) and recent reports dealing with the implementation of cancer screening programmes in the EU (5-7). These references recognize that societal values in addition to professional, technical and scientific standards are of prime importance in any decision to implement cancer screening programmes. Furthermore, the population-based approach to programme implementation as recommended by the Council of the EU and the authors and editors of the European Guidelines is more equitable, more effective and more costeffective than an opportunistic approach. The latter usually leads to overuse of health resources by a portion of the target population with lower cancer risk, and underuse by less advantaged groups with higher cancer risk.
The experience in Europe shows that successful implementation of population-based cancer screening programmes requires long-term political commitment, a comprehensive quality management programme and sustainable resources. In a fully established programme the proportion of the expenditure devoted to quality assurance should be no less than 10-20%, depending on the scale of the programme. In the initial years, this proportion may be substantially higher due to the low volume of screening examinations compared to the situation after complete rollout of a nationwide programme.
Once the political decision has been taken to establish a population-based cancer screening programme, a competent coordinator should receive the mandate to manage the entire process of programme implementation beginning with a planning phase, and followed by feasibility testing, piloting and, depending on the interim results, subsequent gradual rollout of a programme fulfilling the principles and standards recommended in the Council Recommendation (1) 
Introduction
Scientists generate knowledge and evidence with their research results and policy makers have to take decisions. These two worlds have their own dynamics and their own language. However in many instances science can help make better policy decisions. In particular Science Advisory Bodies (SABs) can help to summarize the available evidence and give sound advice to policy makers. They are usually positioned to bridge the gap between the scientists and the policy makers and are able to find a common language in their advisory reports.
In producing a science advisory report common steps in the process can be identified and certain principles need to be addressed at each step. In this methodological framework we present these principles and provide guidelines for streamlining processes according to the principles involved. We start at the basic requirements SABs should fulfil but go on aiming for the "ideal" situation. Some SABs will be further along than others in adopting these guidelines in their daily routines, so ultimately this framework will structure a dynamic process. But we feel it is important to agree on the common principles, underlying the steps in the process of producing science advisory reports, if we want to create a common EUSANH quality seal. 
Annex 4: Evaluation of the advisory process
By the conclusion of the workshop, the Expert Committee had discussed and evaluated the workshop and participation in the development of EuSANH scientific advice. As this information is important and valuable for planning and organising future EuSANH projects, we have summarised some of the experts" comments below.
Workshop planning and preparation
The evidence-based approach was highly appreciated, and it was an advantage that prepared background material had been distributed before the meeting. Despite thorough preparations, there was a need to change direction somewhat during the meeting. All participating experts agreed to this change.
A suggestion for future workshops is to plan two face-to-face meetings, rather than one.
The initial meeting should be held early in the process to frame the questions and discuss the continued approach. Thereafter, the literature search could be performed. At the second meeting, the Committee could work on the evidence and recommendations and prepare the scientific advice. The group agreed that the work process of this current workshop had been facilitated by the fact that many of the experts had collaborated previously on a European level.
Expert Committee
The fact that some of the Committee members knew each other from previous collaboration was recognised as an advantage during the group discussions. Moreover, meeting again was important as the field of cancer screening is constantly changing. The importance of including committee members from the newer EU Member States was also noted.
The chairpersons played an important role throughout the workshop since many participants wanted to express opinions during the intense two-day meeting. Because of the many different expectations on the meeting, the chairs were needed to maintain the focus of the discussion.
Science Advice and funding
The work of a European expert group emphasized the advantages of science advice on a European level. These advantages include access to the best experts at a European level ('Golden network') and collaboration in preparing the scientific base for advisory reports.
The latter helps avoid overlap and duplicate activities, thereby reducing the workloads.
A discussion focused on the different definitions used in association with scientific advice. The importance of communicating "lack of knowledge" was also stressed, as this can be of interest to funders. Since the lack of resources is a common problem in this field, increased cooperation with health technology assessment agencies and science advisory bodies is important.
Dissemination
The discussion highlighted the dissemination of results from this type of project. Some of the Committee members preferred scientific publications, as this is where experts involved in screening programmes find information. However, since many countries contact WHO for information, it is also important to present the results in scientific advice or guidelines.
Future
The Committee foresees an increasing need for expertise in the area of cancer screening in general and in the implementation of cancer screening. An expert network is required to supply this need, especially in countries having limited experience with screening programmes. Since the EC also needs advice from experts, a Standing Committee for screening was suggested. 
Suggested improvements in the advisory process
DETERMINANTS
Pre-decision planning
The starting point must always be to raise professional and public awareness of the purpose, the benefits and the risks of screening. This implies that one has to organize a societal debate. The second step would be to review existing evidence-based recommendations and guidelines and tailor them to the local setting. During the whole process cross border exchange of experience is encouraged.
-Building up of a professional and public understanding of benefits and risks of screening based on: o Collection of information on disease incidence, stage distribution, and survival o Collection of information on availability and quality of cure offered o Understanding the potential role of screening in cancer control o Assessment of evidence for adding screening to existing cancer control measures o Collection of experiences from other countries -Political will, commitment, at all relevant levels (EU, member states and regional) -Decision on political responsibility for the process -Review of existing guidelines -Availability of treatments and facilities (both competence and resources) -Assessment of facilitating factors/barriers for implementation of organised screening -Economic impact and cost-effectiveness of the programme -Formal decision and allocation of budget -Organisation of continuous societal debate and input
Comprehensive planning: feasibility of screening models, professional performance, organisation, financing, and quality assurance (QA)
After the political decision has been taken to start the process of establishing a populationbased cancer screening programme, the first step is comprehensive planning. This should include the entire multidisciplinary screening process as well as the organisational aspects which need to be taken into account in order to avoid unnecessary delays and costs later on.
The feasibility of screening models should be tested before detailed planning of pilot studies can begin. Professional performance, organisational and financial aspects, as well as the scope and content of a comprehensive quality assurance programme should be covered in the planning phase. The initial plans should also define the time frame within which various issues need to be further developed.
-Creation of professional dedication (understanding) -Planning of infrastructure -Establishing of coordinating office with supervision mandate -Ensuring that screening is seen as a process -Appointing a process owner with mandate to run and manage the quality of the programme -Organisational development (self learning, quality driven) -A separate coordination budget -Multidisciplinary case management -Collaboration between screening and treatment systems -Appropriate diagnostic assessment of patients -An appropriate screening monitoring IT-system with access and possibility to link registers e.g., population-, patient-and cancer registers -Comprehensive information system, serving all purposes -Development of a quality assurance (QA) plan, including technical quality -Adoption of approved QA-plan -Definition of performance parameters and acceptable levels for health care providers -Contracts with health care providers -Consideration of accreditation system or other performance control systems -System for auditing, training and re-training -Having tools to exclude bad performers
Preparation of all components of screening process, including feasibility testing
Based on the comprehensive planning, the feasibility of the screening services and key components of programme management may be tested in small-scale studies which are designed to yield initial results with a limited amount of financial, technical, staff and time resources. The study results are taken into account in revising the initial plans, if necessary prior to initiating pilot studies on a larger scale. Before the piloting phase can begin, the outcome of the feasibility phase should be thoroughly evaluated.
-Scientific and ethical review of feasibility protocol -Correct and balanced information on "benefit and risk" -Societal input -Creation of oversight for screening programmes -Scientific publication of outcome
Piloting and modification, if necessary, of all screening systems and components, including quality assurance in routine settings
Having gained experiences from a feasibility phase, screening implementation has basically followed two different routes. In England, programme implementation started in pilot areas, and based on these experiences the programme was scaled up to national coverage. In Finland, programme implementation started in randomly selected cohorts, and was gradually extended to all targeted age groups. The Finnish approach requires a national decision on screening implementation and the availability of a national population register. The Finnish approach does, however, allow the outcome to be evaluated as a randomised controlled trial. The two routes are well illustrated from the implementation of colorectal cancer screening in England (5) and Finland (6), respectively.
If the pilot implementation model is followed, this phase starts with selection of a few pilot settings. Supervision and coaching is important in this phase in order to pick up problems in the screening process as soon as possible. The pilot phase also services as a testing ground for the legal framework.
-Supervision and coaching of screen performers -Working out of the legal framework -Ability to exclude bad performers
Verification of adequacy of pilot performance
The outcome of the piloting should be reported in the scientific literature. Furthermore the outcome should be widely disseminated to health planners, politicians and health professionals. Based on the piloting, the financial implications of the roll-out of the programme should be determined.
-Budgeting -Ensure financial commitment -Scientific publication of outcome
Scaling-up from pilot to service screening
This is the actual implementation of the piloted intervention. All the points below need to be scaled up to the size of the programme. Special attention should be paid to building up societal confidence in the programme.
-Defining and contracting the screening team, defining responsibilities -Setting up of infrastructure for coordination within health care settings -Developing a plan for evaluation -Assuring the supply of medical and other skilled manpower -Multidisciplinary case management -Training, reference centre -Comprehensive information system, serving all purposes -Collaboration between screening, treatment and IT systems -Technical quality assurance -Reducing of barriers to participate -Tools to manage compliance -Advocacy and collaboration with local civil society organisations -Population confidence -Supervision -Ability to exclude bad performers -Provision for testing new technologies -Monitoring benefits and harms of screening -Scientific publication of outcome
Sustainability
Sustainability and plans for long-term evaluation need to be developed. Continuous financial support needs to be ensured. Sustain confidence in the programme. Ensure high quality testing, reporting of screening outcomes and follow-up of screening findings.
-Building population confidence -Ensuring financial resources
DISCUSSION
The importance of screening as a tool in cancer control has been on the EU agenda for more than 20 years. In the European Code Against Cancer from 1989, women were advised to "have a cervical smear regularly" and "if possible, [to] undergo mammography at regular intervals above the age of 50" (7). The need for organisation of screening into population-based programmes was stressed by the first quality assurance guidelines on breast (8) and cervical (9) cancer from 1993 and further developed in the preparatory work for the EU Council recommendation (10) . In the 2003 Council Recommendation, the Member States unanimously agreed to recommend population-based screening for breast, cervical, and colorectal cancer (1).
The actual implementation of population-based screening programmes in EU Member
States is, however, still far from complete. By 2007, close to half of European women were covered only by opportunistic screening for cervical cancer, and 30% of European women and men were not offered screening for colorectal cancer (11), Table 1 . By 2009, the lifetime number of recommended screening tests for cervical cancer varied from 6 to 50+ across the EU member states (12) . Various obstacles in the political priority setting and/or health care systems can impede the implementation of population-based screening. In new Member States, lack of resources is a significant problem. In old Member States, organisation of screening may conflict with a traditional fee-for-service payment system. To decrease the use of opportunistic smears, Dutch doctors were for some period paid for not taking smears; and English doctors were paid only if they reached a high coverage in their patient population. Several countries have encountered problems with data confidentiality, despite the fact that the EU directive on data protection allows for linkages of health services data. The EU obligation to invite tenders for provision of large scale services has also in some cases impeded centralization of some services e.g. cytology.
To ensure successful implementation of a population-based cancer screening programme it is mandatory that there is a broad societal understanding of the benefits and risks, that there is effective local ownership of the programme, and that it follows updated, evidencebased guidelines. Ambitions should not be set too high. In some countries or regions, not all the points listed here may be feasible, and the points have to be seen in the perspective of the actual setting. Having considered the list carefully, a country or a region may decide how to develop a screening programme tailored to the local circumstances. It is better to implement one cancer screening programme at a time, rather than to start screening for all 3 cancer sites at once. The detailed lists provided in this paper can serve as a guide to a gradual and successful implementation.
Given the complexity of the process, it is not surprising that 10 or more years are commonly required to implement population-based cancer screening programmes (11) .
Effective, sustained coordination with a clear vision of the process and adequate resources to provide leadership, develop consensus, and adapt to the evolving needs of programme development is required, beginning early in the process.
CONCLUSION
It is of utmost importance that screening programmes are implemented effectively and operate in accordance with societal values and priorities. A prerequisite for a successful screening programme is the societal acceptance, local ownership, and effective coordination along with the best evidence-based practice. 
